Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2024 16:30 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ET ...
March 06, 2024 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
January 29, 2024 08:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights...
May 11, 2023 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate...
May 09, 2023 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
October 20, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...